title: Didox potentiates the cytotoxic profile of doxorubicin and protects from its cardiotoxicity.
abstract: The use of adjuvant therapies in cancer treatment is rationalized by potentiating the efficacy and/or protecting from the major side effects of chemotherapeutics. Didox, besides its antioxidant properties, is an inhibitor for DNA synthesis and repair which might recommend its use as adjuvant therapy. Herein, we have studied the effect of didox in potentiating the efficacy of doxorubicin (DOX) against liver cancer cells and protecting from its dose-limiting cardiotoxic effects. Didox combination with DOX significantly decreased in the IC50 of DOX to half its original value in Huh7 and HepG2 liver cancer cell lines. The calculated combination index (CI-value) indicated additive type of drug interaction (CI-value ranged from 0.81 to 0.9). Both didox and DOX significantly blocked the cell cycle in S-phase and their combination significantly increased cell cycle blockade. Also, didox combination significantly increase the caspase-3 level compared to DOX treatment alone. On the other hand, didox (150 mg/kg daily) significantly protected the cardiomyocyte membrane integrity and decreased the intra-cardiac oxidative stress induced by DOX treatment (15 mg/kg). This protective effect was reflected in reverting the cardiomegaly and cardio-pathological features induced by DOX treatment. Also didox prolonged the median survival time of mice treated with DOX and decreased the mortality risk by 3.7 folds. In conclusion, didox significantly potentiated the cytotoxicity of DOX in liver cancer cells and protected from its cardiotoxicity.
authors.affiliation: Pharmacology and Toxicology Department, Faculty of Pharmkacy, King Abdulaziz University, Jeddah, Saudi Arabia; Pharmacology Department, Medical division, National Research Center, Dokki, 12622 Giza, Egypt. Electronic address: amalabd@kau.edu.sa.
authors.forename: Ahmed M
authors.initials: AM
authors.lastname: Al-Abd
authors.forename: Fahad A
authors.initials: FA
authors.lastname: Al-Abbasi
authors.forename: Gihan F
authors.initials: GF
authors.lastname: Asaad
authors.forename: Ashraf B
authors.initials: AB
authors.lastname: Abdel-Naim
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology*; D053148:Caspase 3 / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000009:adverse effects* / Q000494:pharmacology*; D004357:Drug Synergism; D006321:Heart / Q000187:drug effects*; D006877:Hydroxamic Acids / Q000494:pharmacology*; D008113:Liver Neoplasms / Q000473:pathology; D008297:Male; D051379:Mice; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D015996:Survival Rate
chemical_list: D002316:Cardiotonic Agents; D006877:Hydroxamic Acids; D004317:Doxorubicin; D011065:Poly(ADP-ribose) Polymerases; D053148:Caspase 3; C035419:3,4-dihydroxybenzohydroxamic acid
keywords: Cardiotoxicity; Didox; Doxorubicin; Liver cancer